Finerenone Boosts HFpEF Quality of Life 03/14/26
Welcome to Cardiology Today â Recorded March 14, 2026. This episode summarizes 5 key cardiology studies on topics like Pressure microcatheter and Fractional flow reserve. Key takeaway: Finerenone Boosts HFpEF Quality of Life.
Article Links:
Article 1: Heart failure patients with reduced or mildly reduced ejection fraction: baseline characteristics of the low-dose digoxin outcome DECISION trial. (European journal of heart failure)
Article 2: Finerenone and Quality of Life in Heart Failure: Component-Level Analyses and Clinical Relevance of the Kansas City Cardiomyopathy Questionnaire. (European journal of heart failure)
Article 3: Infective Endocarditis After Arrythmia Device Implantation in Cardiac Surgery Patients. (Journal of the American Heart Association)
Article 4: Impact of Combined Anticoagulant and Antiplatelet Therapy in Older Patients With Atrial Fibrillation: ANAFIE Subanalysis. (Journal of the American Heart Association)
Article 5: Clinical Validation of a Novel Pressure Microcatheter-Based Nonhyperemic Pressure Ratio (SUPREME II Study). (Journal of the American Heart Association)
Full episode page: https://podcast.explainheart.com/podcast/finerenone-boosts-hfpef-quality-of-life-03-14-26/
đ Featured Articles
Article 1: Heart failure patients with reduced or mildly reduced ejection fraction: baseline characteristics of the low-dose digoxin outcome DECISION trial.
Journal: European journal of heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41823368
Summary: This report provided the detailed baseline characteristics of patients enrolled in the D.E.C.I.S.I.O.N. trial. It established the specific clinical profile of contemporary heart failure patients with reduced or mildly reduced left ventricular ejection fraction who are receiving low-dose digoxin or placebo. The report positioned these patient characteristics against those observed in previous cardiac glycoside trials such as D.I.G. and D.I.G.I.T. minus H. F., providing a comparative context for future outcome data. The study design, a randomized, double-blind, placebo-controlled outcome trial, demonstrated its focus on evaluating digoxin’s effects in this defined population.
Article 2: Finerenone and Quality of Life in Heart Failure: Component-Level Analyses and Clinical Relevance of the Kansas City Cardiomyopathy Questionnaire.
Journal: European journal of heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41817207
Summary: Finerenone improved the overall health status of patients with heart failure with mildly reduced or preserved ejection fraction, as measured by the aggregate 23-item Kansas City Cardiomyopathy Questionnaire score. This prespecified analysis from the F.I.N.E.A.R.T.S. minus H. F. trial contextualized these improvements, demonstrating the clinical relevance of K.C.C.Q. changes for both patients and clinicians. The findings enhance the understanding of how finerenone impacts patient quality of life in this specific heart failure population.
Article 3: Infective Endocarditis After Arrythmia Device Implantation in Cardiac Surgery Patients.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41823269
Summary: This nationwide registry-based study identified the risk of infective endocarditis after cardiac implantable electronic device implantation within 30 days of cardiac surgery. The study established specific risk factors associated with this complication in patients undergoing first-time cardiac surgery in Sweden. Findings demonstrated that patients in this cohort, without previous cardiac implantable electronic devices, experience an increased risk of infective endocarditis. These results highlight the need for vigilance and targeted strategies in this vulnerable patient population.
Article 4: Impact of Combined Anticoagulant and Antiplatelet Therapy in Older Patients With Atrial Fibrillation: ANAFIE Subanalysis.
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41823252
Summary: This A.N.A.F.I.E. subanalysis evaluated the clinical outcomes of combined oral anticoagulant and antiplatelet therapy versus oral anticoagulant monotherapy in patients aged 75 years or older with nonvalvular atrial fibrillation. The study established the differential impact of these two treatment approaches on clinical endpoints in an elderly Japanese cohort. The findings provided crucial comparative data for managing older atrial fibrillation patients, informing decisions about optimal antithrombotic strategies. This prospective multicenter observational study contributes to understanding medication effects in a high-risk population.
Article 5: Clinical Validation of a Novel Pressure Microcatheter-Based Nonhyperemic Pressure Ratio (SUPREME II Study).
Journal: Journal of the American Heart Association
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41823250
Summary: This S.U.P.R.E.M.E. two study introduced and described the constant resistance ratio, a novel nonhyperemic pressure ratio derived from piezoresistive pressure microcatheter measurements. The investigation performed repeated measurements to compare the diagnostic performance of this constant resistance ratio against fractional flow reserve in coronary lesions with 30 percent to 90 percent diameter stenosis. The study established the operational methodology for applying this new microcatheter-based technique to assess coronary physiology. Its findings provided a direct comparison between these two assessment modalities, enhancing understanding of nonhyperemic pressure ratios.
đ Transcript
Today’s date is March 14, 2026. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Heart failure patients with reduced or mildly reduced ejection fraction: baseline characteristics of the low-dose digoxin outcome DECISION trial. This report provided the detailed baseline characteristics of patients enrolled in the D.E.C.I.S.I.O.N. trial. It established the specific clinical profile of contemporary heart failure patients with reduced or mildly reduced left ventricular ejection fraction who are receiving low-dose digoxin or placebo. The report positioned these patient characteristics against those observed in previous cardiac glycoside trials such as D.I.G. and D.I.G.I.T. minus H. F., providing a comparative context for future outcome data. The study design, a randomized, double-blind, placebo-controlled outcome trial, demonstrated its focus on evaluating digoxin’s effects in this defined population.
Article number two. Finerenone and Quality of Life in Heart Failure: Component-Level Analyses and Clinical Relevance of the Kansas City Cardiomyopathy Questionnaire. Finerenone improved the overall health status of patients with heart failure with mildly reduced or preserved ejection fraction, as measured by the aggregate 23-item Kansas City Cardiomyopathy Questionnaire score. This prespecified analysis from the F.I.N.E.A.R.T.S. minus H. F. trial contextualized these improvements, demonstrating the clinical relevance of K.C.C.Q. changes for both patients and clinicians. The findings enhance the understanding of how finerenone impacts patient quality of life in this specific heart failure population.
Article number three. Infective Endocarditis After Arrythmia Device Implantation in Cardiac Surgery Patients. This nationwide registry-based study identified the risk of infective endocarditis after cardiac implantable electronic device implantation within 30 days of cardiac surgery. The study established specific risk factors associated with this complication in patients undergoing first-time cardiac surgery in Sweden. Findings demonstrated that patients in this cohort, without previous cardiac implantable electronic devices, experience an increased risk of infective endocarditis. These results highlight the need for vigilance and targeted strategies in this vulnerable patient population.
Article number four. Impact of Combined Anticoagulant and Antiplatelet Therapy in Older Patients With Atrial Fibrillation: ANAFIE Subanalysis. This A.N.A.F.I.E. subanalysis evaluated the clinical outcomes of combined oral anticoagulant and antiplatelet therapy versus oral anticoagulant monotherapy in patients aged 75 years or older with nonvalvular atrial fibrillation. The study established the differential impact of these two treatment approaches on clinical endpoints in an elderly Japanese cohort. The findings provided crucial comparative data for managing older atrial fibrillation patients, informing decisions about optimal antithrombotic strategies. This prospective multicenter observational study contributes to understanding medication effects in a high-risk population.
Article number five. Clinical Validation of a Novel Pressure Microcatheter-Based Nonhyperemic Pressure Ratio (SUPREME II Study). This S.U.P.R.E.M.E. two study introduced and described the constant resistance ratio, a novel nonhyperemic pressure ratio derived from piezoresistive pressure microcatheter measurements. The investigation performed repeated measurements to compare the diagnostic performance of this constant resistance ratio against fractional flow reserve in coronary lesions with 30 percent to 90 percent diameter stenosis. The study established the operational methodology for applying this new microcatheter-based technique to assess coronary physiology. Its findings provided a direct comparison between these two assessment modalities, enhancing understanding of nonhyperemic pressure ratios.
Thank you for listening. Don’t forget to subscribe.
đ Keywords
Pressure microcatheter, Fractional flow reserve, Cardiac glycosides, Antiplatelet drugs, Quality of life, Risk factors, Cardiac surgery, Antithrombotic therapy, Postoperative complications, Heart failure with preserved ejection fraction, Constant resistance ratio, Health status, Infective endocarditis, Kansas City Cardiomyopathy Questionnaire, Finerenone, Left ventricular ejection fraction, Coronary lesions, Cardiac implantable electronic devices, Heart failure, Nonhyperemic pressure ratio, Clinical trial, Elderly patients, Oral anticoagulants, Atrial fibrillation, Digoxin.
âšī¸ About
Concise summaries of cardiovascular research for professionals.
Subscribe âĸ Share âĸ Follow